# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	Responses)																	
Name and Address of Reporting Person * Thomley Richard					2. Issuer Name <b>and</b> Ticker or Trading Symbol PRESSURE BIOSCIENCES INC [PBIO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
(Last) (First) (Middle) C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE.					3. Date of Earliest Transaction (Month/Day/Year) 12/12/2013								X Officer (give title below) Other (specify below)  Chief Financial Officer					
(Street)				4	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ Form	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
SOUTH EASTON, MA 02375												Form	Form filed by More than One Reporting Person					
(City)		(State)	(Zip)				Ta	ble I	- Non-D	erivativ	e Securities A	cquired, Di	sposed o	f, or Benefi	icially Owned			
(Instr. 3)			2. Transact Date (Month/Da		2A. Deemed Execution Date ear) any (Month/Day/Y			(Instr. 8)		(A) or	urities Acquire Disposed of ( 3, 4 and 5)  (A) or Int (D) Pr	D) Owned Transac	Transaction(s) (Instr. 3 and 4)		O F D oi (I	wnership of Be irect (D) Ov Indirect (In	neficial vnership	
Reminder: Re	port on a sep	arate line for each cl		ble II -	Derivat	ive S	ecurities	Acq	Pers in th a cu uired, Di	ons whis form		uired to re ontrol nun ally Owned	spond unber.		on contained		74 (9-02)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security				if Transaction of Code De Acc (A Dix (Instr. 8) Code Code Code Code Code Code Code Code			rivative (Meaning of the courities quired of the courities of the couring of the		Oate Exercisable and piration Date onth/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	· V	(A)	(D)	Date Exercisa	ible	Expiration Date	Title	Amount or Number of Shares					
Series K Convertible Preferred Stock	\$ 0.25	12/12/2013			P		20		12/12/2	2013 <sup>(1)</sup>	12/12/2014	Common Stock	20,000	(2)	20,000	D (1)		
Series K Common Stock Purchase Warrant	\$ 0.3125	12/12/2013			P		10,000		12/12/2	2013(3)	12/12/2016	Common Stock	10,000	(2)	10,000	D (3)		
Reporti	ing Ow	ners																
Reporting Owner Name / Address				Relationships														
Thomley Richard C/O PRESSURE BIOSCIENCES, INC. 14 NORFOLK AVE. SOUTH EASTON, MA 02375			Director	10% (	Chief Financial Officer  Chief Financial Officer													

## **Signatures**

/s/Richard Thomley	12/16/2013
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The terms of the Series K Convertible Preferred Stock contain a limitation on conversion which prevents the Reporting Person from converting shares of Series K Convertible Preferred Stock if, after giving effect to the conversion, the Reporting Person would beneficially own more than 4.99% of the outstanding shares of Common Stock. The Reporting Person may elect (1) to increase this limitation to 9.99%, 14.99%, or 19.99% upon not less than 61 days prior written notice to the Company. Since the Reporting Person currently beneficially owns less than 4.99% of the outstanding shares of Common Stock, the conversion limitation that applies to the Reporting Person is the 4.99% limitation. The Reporting Person disclaims beneficial

ownership of such securities except to the extent of the Reporting Person's pecuniary interest in such securities.

Pursuant to a certain Securities Purchase Agreement dated December 12, 2013, among the Company, the Reporting Person, and the other purchasers named therein, the Reporting Person

- (2) purchased 20 "Units" at a purchase price of \$250 per Unit. Each Unit consisted of (i) one share of Series K Convertible Preferred Stock, convertible into 1,000 shares of the Company's Common Stock, and (ii) a warrant to purchase 500 shares of Common Stock, which warrant is exercisable until December 12, 2016.

  The Series K Common Stock Purchase Warrants contain a limitation on exercise which prevents the Reporting Person from exercising any Warrants if, after giving effect to the exercise, the Reporting Person would beneficially own more than 4.99% of the outstanding shares of Common Stock. The Reporting Person may elect to increase this limitation to 9.99%, 14.99%, or (3) 19.99% upon not less than 61 days prior written notice to the Company. Since the Reporting Person currently beneficially owns less than 4.99% of the outstanding shares of Common Stock, the exercise limitation that applies to the Reporting Person is the 4.99% limitation. The Reporting Person disclaims beneficial ownership of such securities except to the extent of the Reporting Person's pecuniary interest in such securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.